Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non–muscle-invasive Bladder Cancer
Authors:
- Tine Ginnerup AndreasenTATine Ginnerup Andreasen
- Trine StrandgaardTSTrine Strandgaard
- Tessa Jane DivitaTDTessa Jane Divita
- Kristine Young-HalvorsenKYKristine Young-Halvorsen
- Anders NeijberANAnders Neijber
- Lars DyrskjøtLDLars Dyrskjøt
Open Access
- 8 August 2026
- journal article
- Published by Elsevier in European Urology Open Science
- Vol. 91, 74-83
Abstract
No abstract availableFunding Information
- Photocure
This publication has 22 references indexed in Scilit:
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines UpdateEuropean Urology, 2024
- Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder CancerEuropean Urology Open Science, 2023
- Bladder cancerNature Reviews Disease Primers, 2023
- Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non–muscle-invasive Bladder CancerEuropean Urology, 2022
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapyCancer Treatment Reviews, 2018
- The mechanism of action of BCG therapy for bladder cancer—a current perspectiveNature Reviews Urology, 2014
- Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw DataEuropean Urology, 2013
- The multiple faces of CCL13 in immunity and inflammationInflammopharmacology, 2013
- T cell exhaustionNature Immunology, 2011
- Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysisInternational Journal of Technology Assessment in Health Care, 2011